Sarepta Therapeutics, Inc. et al. vs. Genzyme Corporation et al.

Explore the PTAB proceeding IPR2026-00150 filed by Sarepta Therapeutics, Inc. et al. on 2025-11-25. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2026-00150

Filing Date

2025-11-25

Accorded Filing Date

2025-11-25

Institution Decision Date

2026-05-06

Last Modified Date

2026-09-11

Proceeding Type

IPR

Termination Date

—

Trial Status

Trial Instituted

Parties & Counsel

Petitioner

Sarepta Therapeutics, Inc. et al.

Represented By

Wilson, Robertet al

Patent Owner / Respondent

Genzyme Corporation et al.

Represented By

Antons, Amandaet al

Tribunal & Venue

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Patent Information

1 Patent Involved

Respondent Application Number 18513970

Respondent Patent Number 12031894

External Links

Espacenet

Google Patents

Respondent Inventor Catherine R. O'RIORDAN et al

Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Address and Attorney/Agent Information

40 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name Sanofi/Genzyme c/o Morrison & Foerster LLP

Customer Number 89300

Address 755 Page Mill Road, Palo Alto, CA, 94304, UNITED STATES

Attorney / Agent Information

Reg #	Name	Phone
36844	Joseph Kirk Jr	908-981-6911
39150	John Conway	908-981-6688
40564	Anne Collins	978-341-0036
44045	Sandra Brockman-Lee	857-523-9199
45736	Pamela Torpey	508--27-1-0683
45979	Milan Vinnola	619-238-0062
47150	Nicole Parsons	617-685-5697
52610	Kelly Bender	2485930581
54154	Allyson Hatton	508-361-7392
54958	Janann Ali	617-685-5645
58163	Alejandro Martinez	617-685-5935
59682	Jeremy Bond	617-685-5653
61358	Ryan Mcquade	617-838-5595
61393	Isaac Hubner	617-866-4544
62108	Siew Chong	973-980-0397
63001	Stephanie Donahue	908-331-4406
63750	Mayssam Ali	617-685-5646
64259	Xuemei Peng	908-981-6951
64740	Alan Townsley	202-857-2278
64828	Jeffrey Weber	617-685-6431
66863	Patricia Callanan	617-866-4404
67265	Yi Wang	617-685-5735
67340	Dhruv Kaushal	617-245-4065
68308	Jonathan Andron	617-685-5658
68315	Meenakshy Chakravorty	781-418-9211
69032	Robert Bolcome Iii	857-331-1597
69052	Jing Wang	617-951-8720
69953	Janet Tse	617-564-6571
70740	Erika Wallace	617-937-1397
71226	Meghan Klaric	313-465-7211
72110	Daniel Tate	800-981-2491
72475	Indrani Dasgupta	617-685-5977
72868	David Lefebvre	617-685-5338
72919	Ted Ririe	385-312-6536
74124	Evan King	781-234-4286
75427	Shirley Tan	617-646-8444
77001	Sara Haines	003-348-1492783
80264	Christopher Marion	314-517-7022
80424	Victoria Pedanou	508-736-4409
81386	Erin May	617-251-9709

Proceeding Documents

124

Updated Mandatory Notices NOTICE

2026-09-11 FILING PARTY: PETITIONER

Download

Updated Power of Attorney NOTICE

2026-09-11 FILING PARTY: PETITIONER

Download

Petitioner's Objections to Evidence OTHER

2026-08-12 FILING PARTY: PETITIONER

Download

Panel Change Order ORDER

2026-08-07 FILING PARTY: BOARD

Download

2041

B. Kokona et al., Particle Size Distribution Resolution Limit of AAV High-Speed Sedimentation Velocity Protocol Relative to Low-Speed Sedimentation Velocity Protocol, Mass Photometry, and Charge-Detection Mass Spectrometry Exhibit

2026-08-05 FILING PARTY: PATENT OWNER

Download

Sarepta Therapeutics, Inc. et al. vs. Genzyme Corporation et al.

Proceeding Overview

Parties & Counsel

Petitioner

Sarepta Therapeutics, Inc. et al.

Represented By

Patent Owner / Respondent

Genzyme Corporation et al.

Represented By

Tribunal & Venue

Patent Information

Address and Attorney/Agent Information

Power of Attorney & Correspondence

Attorney / Agent Information

Proceeding Documents

Updated Mandatory Notices NOTICE

Updated Power of Attorney NOTICE

Petitioner's Objections to Evidence OTHER

Panel Change Order ORDER

B. Kokona et al., Particle Size Distribution Resolution Limit of AAV High-Speed Sedimentation Velocity Protocol Relative to Low-Speed Sedimentation Velocity Protocol, Mass Photometry, and Charge-Detection Mass Spectrometry Exhibit

D.M. Lipinski et al., Clinical Applications of Retinal Gene Therapy Exhibit

BioAnalysis, “Empty/Full/Partial Capsid Assay Using Sedimentation Velocity Analytical Ultracentrifugation (SV-AUC)” Exhibit

Declaration of Karen G. Fleming, PH.D. Exhibit

Google Scholar Results for Citations to Burnham Exhibit

S.A. Berkowitz & T. Laue, Boundary Convection During Sedimentation Velocity in the Optima Analytical Ultracentrifuge Exhibit

Curriculum Vitae of Barrie J. Carter Exhibit

S.A. Berkowitz et al., Rapid High-Resolution Size Distribution Protocol for Adeno-Associated Virus Using High Speed SV-AUC Exhibit

A. Roy et al., “Antigenic Differences Among AAV Species of Different Densities” Exhibit

Declaration of Barrie J. Carter (“Carter”) Exhibit

Deposition Transcript of Steven Berkowitz Exhibit

Patent Owner's Response RESPONSE

Sigma-Aldrich, “Strategies for the Separation and Analysis of Empty and Filled Capsids During Viral Vector Production” Exhibit

Notice of Deposition of Steven Berkowitz NOTICE

Joint Stipulation to Modify Due Dates 1-3 OTHER

Panel Change Order ORDER

Order Denying Director Review of Institution Decision REHEARING

Authorized Response to Director Review Request OTHER

Petitioner's Objections to Evidence OTHER

Patent Owner's Request for Director Review REQUEST

Patent Owner's Objections to Evidence OTHER

Ex. 3100 Counsel email for authorized response Exhibit

SCHEDULING ORDER ORDER

Institution Decision: Grant DECISION

Director Discretionary Decision: Refer RESPONSE

Ex. 1046 Exhibit

Ex. 1047 Exhibit

Ex. 1044 Exhibit

Ex. 1050 Exhibit

Ex. 1043 Exhibit

Ex. 1048 Exhibit

Ex. 1049 Exhibit

Ex. 1045 Exhibit

Ex. 1042 Exhibit

Response to Patent Owner's Discretionary Denial Brief RESPONSE

Oliver, Christopher, Diffusion Coefficient and Molecular Weight of Type 5 Adenovirus Exhibit

Patent Owner's Preliminary Response POPR

Curriculum Vitae of Declaration of Karen G. Fleming, Ph.D. Exhibit

J.F. Wright, Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment Exhibit

Declaration of Karen G. Fleming, Ph.D. Exhibit

Tanford, Charles, Physical Chemistry of Macromolecules (1961) Exhibit

Q. Xie et al., The Atomic Structure of Adeno-Associated Virus (AAV-2), a Vector for Human Gene Therapy Exhibit

T. Matsushita et al., Adeno-Associated Virus Vectors Can Be Efficiently Produced Without Helper Virus Exhibit

D. Curran-Everett, Explorations in Statistics: Hypothesis Tests and P-values Exhibit

Novartis Gene Therapies, Inc. v. Genzyme Corp., IPR2023-01044,Paper 12 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 110 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 87 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 78 Exhibit

US 2017/0362608 to McLaughlin et al. Exhibit

Novartis Gene Therapies, Inc. v. Genzyme Corp., IPR2023-01044,Paper 1 Exhibit

Burnham et al., Analytical Ultracentrifugation as an Approach to Characterize Recombinant AAV Vectors Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 102 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 28 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 91 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 99 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 59 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 76 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 37 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) - Defendant’s Supplemental Initial Invalidity Contentions Exhibit

Patent Owner's Request for Discretionary Denial RESPONSE

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 35 Exhibit